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Introduction {#sec1}
============

The HIV-1 "accessory proteins" Vif, Vpr, Vpu, and Nef function by binding host proteins and recruiting them to cellular degradation machinery, resulting in depletion of these target substrates ([@bib56], [@bib79], [@bib80], [@bib81]). Some targets of Vif, Vpu, and Nef, such as APOBEC3 family members, Tetherin, and SERINC3/SERINC5, are dominantly acting viral restriction factors, and their degradation is therefore thought to directly enhance *in vivo* viral replication. Conversely, the role of Vpr in enhancing viral replication remains unclear.

Unlike other accessory proteins, Vpr is packaged into nascent viral particles and delivered into newly infected cells, and it is therefore present in the earliest stages of the viral replication cycle. Although Vpr does not enhance *in vitro* viral replication in most experimental systems, a number of cellular phenotypes have been ascribed to it; it has been described as an "enigmatic multitasker" ([@bib24]). For example, expression of Vpr has variously been reported to cause arrest of cycling cells at the G2/M phase, apoptosis, enhancement of HIV gene expression, and stimulation or inhibition of key signaling pathways such as nuclear factor κB (NF-κB) and nuclear factor of activated T cells (NFAT) ([@bib2], [@bib16], [@bib43], [@bib69], [@bib74]).

Although the mechanisms by which Vpr causes such complex effects is controversial, most reports agree that they depend on Vpr interacting with a cellular E3 ligase complex containing DCAF1, DDB1, and Cul4 ([@bib13], [@bib45]). As with the other accessory proteins, Vpr is therefore presumed to function by recruiting cellular factors to this E3 ligase complex, resulting in their subsequent degradation. Accordingly, several host factors depleted by Vpr have been identified, but their connection to Vpr-associated cell biological phenotypes is generally unclear, as is their role in regulating viral replication *in vivo* ([@bib27], [@bib32], [@bib41], [@bib42], [@bib51], [@bib57], [@bib72], [@bib75], [@bib96]).

We previously used unbiased quantitative proteomics to map temporal changes in cellular protein abundance during HIV infection of CEM-T4 T cells and identify targets of Vpu (SNAT1), Nef (SERINC3/5), and Vif (PPP2R5A-E) ([@bib23], [@bib55]). Nonetheless, known accessory protein targets only account for a tiny fraction of all HIV-dependent protein changes observed in our experiments ([@bib23]). Given the varied cell biological phenotypes ascribed to Vpr, we hypothesized that it may be responsible for some of the remaining changes. Therefore, in this study, we undertake a comprehensive analysis of the effects of Vpr on the cellular proteome of HIV-1-infected cells and combine this with further unbiased approaches to identify cellular proteins directly targeted and degraded by Vpr. Our data suggest a model for the effects of Vpr on cells in which promiscuous targeting of host factors distinguishes it from other HIV accessory proteins.

Results {#sec2}
=======

Vpr Is Required for Global Proteome Remodeling in HIV-Infected Cells {#sec2.1}
--------------------------------------------------------------------

First, we compared total proteomes of uninfected CEM-T4 T cells with cells infected with either wild-type (WT) HIV or an HIV Vpr deletion mutant (HIV ΔVpr) at an infectious MOI of 1.5 ([Figure 1](#fig1){ref-type="fig"}A), resulting in approximately 75% infection ([Figure 1](#fig1){ref-type="fig"}B). Data from this experiment are available, together with the other proteomics datasets presented here, in a readily searchable interactive format in [Table S1](#mmc2){ref-type="supplementary-material"}. As expected, among the 7,774 quantitated proteins, we observed widespread changes in cells infected with wild-type HIV ([Figure 1](#fig1){ref-type="fig"}C left panel). Together with known Nef, Vpu, and Vif targets, we saw depletion of previously reported Vpr targets, including HLTF ([@bib32], [@bib42]), ZGPAT ([@bib57]), MCM10 ([@bib72]), UNG ([@bib75]), TET2 ([@bib51]), and MUS81 and EME1 ([@bib41], [@bib96]). DCAF1, part of the ligase complex used by Vpr to degrade targets, was also depleted, consistent with a previous report ([@bib44]).Figure 1Proteomic Analysis of the Effect of Vpr in HIV Infection(A) Graphical summary of the HIV and ΔVpr HIV infection TMT experiment.(B) Fluorescence-activated cell sorting (FACS) plots showing quantification of infection in an example replicate for each of the three conditions. Infected cells lose CD4 expression and become GFP-positive.(C) Scatterplots displaying pairwise comparisons between wild type, ΔVpr, and mock-infected cells. Each point represents a single protein, with HIV proteins and host proteins of interest highlighted with different symbols (see key).(D) Principal-component analysis of the samples in this experiment, with wild-type infected (red), ΔVpr (blue), and mock-infected (gray) replicates.See also [Table S1](#mmc2){ref-type="supplementary-material"}.

In HIV ΔVpr infection ([Figure 1](#fig1){ref-type="fig"}C, right panel), depletion of Nef, Vpu, and Vif targets was maintained. Remarkably, as well as abolishing depletion of known Vpr targets, almost all of the previously uncharacterized protein changes were also reduced or abolished in HIV ΔVpr infection. Although 1,940 proteins changed significantly (q \< 0.01) in wild-type HIV-infected cells, only 45 significant changes occurred in cells infected with HIV ΔVpr. Indeed, principal-component analysis showed that cells infected with the HIV ΔVpr virus are more similar on the proteome level to uninfected cell than to cells infected with the wild-type virus ([Figure 1](#fig1){ref-type="fig"}D).

Incoming Vpr Protein Alone Drives Global Cellular Proteome Remodeling {#sec2.2}
---------------------------------------------------------------------

Because Vpr enhances the expression of other viral proteins ([@bib20], [@bib22]; [Figure 1](#fig1){ref-type="fig"}C), differences between wild-type and ΔVpr viruses could potentially be explained by secondary changes in expression levels of other proteins or different rates of progression of wild-type and ΔVpr viral infection. To eliminate these potential confounders, we next examined the effect of Vpr acting alone. Unlike other HIV-1 accessory proteins, Vpr is specifically packaged into nascent viral particles. We therefore repeated our proteomics analysis using CEM-T4 T cells exposed to lentiviral particles lacking or bearing Vpr in the presence of reverse transcriptase inhibitors (RTis). This approach excludes all *de novo* viral protein expression, focusing on changes induced by incoming Vpr delivered directly by virions ([Figure 2](#fig2){ref-type="fig"}A). For these experiments, cells were exposed to viral particles at an infectious MOI of 0.5 (determined in the absence of RTis).Figure 2Analysis of the Nature of Vpr-Mediated Proteome Remodeling(A) Graphical summary of the Vpr viral particle TMT experiment. Three replicates of cells exposed to empty viral particles or Vpr-bearing viral particles along with single replicates of cells exposed to viral particles bearing five different Vpr mutants were analyzed.(B) Scatterplot displaying pairwise comparison between cells exposed to empty or Vpr-bearing viral particles.(C). Scatterplot comparing pairwise comparisons from two proteomics experiments, demonstrating the effect of Vpr in the context of HIV-1 infection (x axis, as shown in [Figure 1](#fig1){ref-type="fig"}A) or through cellular exposure to Vpr protein alone (y axis, as shown in [Figure 2](#fig2){ref-type="fig"}A). Labeled proteins were selected for confirmation by immunoblot in (D).(D) Immunoblot of selected proteins in CEM-T4 T cells transduced with an empty vector lentivirus or Vpr-encoding lentivirus 48 h after transduction.(E) Top: immunoblot of purified virus preparations used to infect cells for the proteomics experiment displayed in (A). Changes to amino acid sequence may reduce the affinity of antibody binding. Bottom: bar chart showing the average scaled abundance of matrix, capsid, and integrase peptides detected in the cell lysate by MS. Bars show mean and SD.(F) 7-AAD stain of cells exposed to empty vector, Vpr wild-type, or Vpr mutants. Watson pragmatic modeling was used to identify cells in G1 (blue), S (gray), or G2/M (red) phase.(G) Scatterplots showing pairwise comparison of each Vpr mutant tested and empty vector control, with defined groups of 302 Vpr-depleted and 413 increased proteins highlighted in blue and red, respectively.(H) Heatmap showing the behavior of the 100 proteins most depleted by Vpr particles (blue) and increased (red) within the defined significantly modulated subsets. Color indicates the log~2~ fold change of each protein in each condition compared with empty-particle treatment. Genes were clustered using uncentered Pearson correlation and centroid linkage, and conditions were clustered by column means.See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

Strikingly, changes induced by Vpr-containing viral particles phenocopied the Vpr-dependent proteome remodeling seen in HIV infection ([Figure 2](#fig2){ref-type="fig"}B) with a high degree of correlation (r^2^ = 0.67; [Figure 2](#fig2){ref-type="fig"}C). Taking both experiments together, Vpr is both necessary and sufficient to cause significant (q \< 0.01) depletion of at least 302 proteins and upregulation of 413 (highlighted in blue and red, respectively, in [Figure 2](#fig2){ref-type="fig"}C). This is a stringent false discovery rate, and, in practice, the number of Vpr-dependent changes is almost certainly even higher. Where antibodies were available, we confirmed a proportion of these changes by immunoblot ([Figure 2](#fig2){ref-type="fig"}D).

Cellular Proteome Remodeling Requires Interaction with DCAF1 and Cellular Substrates {#sec2.3}
------------------------------------------------------------------------------------

Although the function or functions of Vpr remain controversial, in all phenotypic descriptions, Vpr activity is dependent on the interaction between Vpr and the DCAF1/DDB1/Cul4 ligase complex, recruitment of which results in ubiquitination and degradation of known Vpr targets by the ubiquitin-proteasome system ([@bib13]). Therefore, in addition to testing the effect of wild-type Vpr protein, we tested a number of previously described mutant Vpr variants ([Figure 2](#fig2){ref-type="fig"}A). [Figure 2](#fig2){ref-type="fig"}E shows an immunoblot of the Vpr protein delivered in the viral particles (top panel) and the abundance of Gag-Pol peptides in the cellular lysate at 48 h determined from the tandem mass tag (TMT) mass spectrometry (MS) experiment. Incoming Vpr alone was sufficient to cause arrest at G2/M, as described previously ([@bib66]), and [Figure 2](#fig2){ref-type="fig"}F shows 7-aminoactinomycin D (7-AAD) DNA staining to determine the extent of G2/M arrest under each condition. Visualizations of the proteome remodeling caused by each mutant are shown in [Figures 2](#fig2){ref-type="fig"}G and 2H.

Because the Q65 residue of Vpr is required for the interaction with DCAF1 ([@bib45]), we first compared proteome changes caused by a Q65R Vpr mutant with wild-type Vpr. As predicted, Q65R Vpr was almost completely inactive ([Figures 2](#fig2){ref-type="fig"}G and 2H). We recapitulated this finding by comparing the effects of wild-type Vpr in control cells or cells depleted of DCAF1 ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Short hairpin RNA (shRNA)-mediated depletion of DCAF1 resulted in an approximately 50% reduction in protein abundance of DCAF1 ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Because a proportion of cellular DCAF1 was still expressed, known Vpr effects, including degradation of HLTF and upregulation of CCNB1, were partially rather than completely inhibited ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Consistent with this, Vpr-mediated changes were broadly reduced in magnitude in DCAF1 knockdown cells ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Thus, as with depletion of known Vpr targets, extensive Vpr-dependent proteomic remodeling is dependent on the interaction of Vpr with its cognate DCAF1/DDB/Cul4 ligase. Importantly, depletion of DCAF1 alone did not phenocopy Vpr-mediated proteome remodeling, and the widespread effects of Vpr are therefore unlikely to result from sequestration and/or depletion of DCAF1.

Residues E24, R36, Y47, D52, and W54 of Vpr are also required for recruitment and degradation of previously described Vpr targets and have been reported to form the substrate-binding surface ([@bib32], [@bib77], [@bib92]). In particular, Y47, D52, and W54 make up the proposed DNA-mimicking motif by which Vpr binds the cellular target UNG2 ([@bib92]). In agreement, the Vpr~E24R,\ R36P~ and Vpr~W54R~ mutants showed attenuated remodeling of the proteome, whereas a triple mutant, Vpr~Y47A,\ D52A,\ W54R~, was defective for almost all Vpr-dependent protein changes ([Figures 2](#fig2){ref-type="fig"}G and 2H). Global protein remodeling therefore depends on both the substrate binding surfaces of Vpr and recruitment of DCAF1, suggesting that this process is mediated by recruitment of Vpr substrates to the DCAF1/DDB1/CUL4 E3 ligase complex and their subsequent degradation.

Vpr causes G2/M arrest in cycling cells, but the mechanism remains contentious ([@bib3], [@bib4], [@bib21], [@bib22], [@bib28], [@bib41], [@bib47], [@bib69], [@bib72], [@bib83]), as is the connection to the replicative advantage Vpr provides *in vivo*. To investigate this important issue, we took advantage of previously characterized Vpr mutants. Residue S79 of Vpr is required for Vpr-dependent cell cycle arrest ([@bib95]; [Figure 2](#fig2){ref-type="fig"}F). Of the other mutants we tested, Vpr~Q65R~ and Vpr~Y47A,\ D52A,\ W54R~ are also unable to cause G2/M arrest, Vpr~E24R,\ R36P~ had an intermediate phenotype, and Vpr~W54R~ caused G2/M arrest at wild-type levels ([Figure 2](#fig2){ref-type="fig"}F). Strikingly, most Vpr-dependent protein changes were also observed with the Vpr~S79A~ mutant ([Figures 2](#fig2){ref-type="fig"}G and 2H) and are therefore independent of G2/M cell cycle arrest. The presence or absence of G2/M arrest was also a poor correlate of proteomic remodeling across the entire panel of mutants. Cell cycle arrest therefore only explains a minority of Vpr-dependent changes ([Figures 2](#fig2){ref-type="fig"}G and 2H).

To confirm this finding, we examined published datasets describing proteins increased or depleted during different phases of the cell cycle or in chemically G2/M-arrested cells ([@bib17], [@bib52]; [Figure S2](#mmc1){ref-type="supplementary-material"}). Compared with cells exposed to Vpr in our study, cells arrested in G2 using a PLK1 inhibitor showed similar regulation of the cyclin family of proteins ([Figure S2](#mmc1){ref-type="supplementary-material"}B), but there was little other correlation between these datasets. Thus, although some changes in protein levels induced by Vpr may be explained by the effects of cell cycle arrest, proteins regulated by the cell cycle in these datasets only account for a minority of Vpr-dependent changes ([Figures S2](#mmc1){ref-type="supplementary-material"}A, S2C, and S2D).

Vpr Directly Targets Multiple Nuclear Proteins with Nucleic Acid Binding Activity {#sec2.4}
---------------------------------------------------------------------------------

Vpr has nuclear localization, and all reported direct Vpr targets are nuclear proteins. Primary Vpr targets are therefore predicted to be nuclear. Conversely, secondary effects resulting from, for example, transcriptional changes should be distributed across the cell. Analysis of the 302 proteins depleted by Vpr revealed profound enrichment for proteins that reside in the nucleus (\>80%) ([Figure 3](#fig3){ref-type="fig"}A, left). This raised the possibility that a significant proportion of proteins depleted by Vpr are directly targeted by Vpr because secondary effects should not be limited to the nucleus. Consistent with this hypothesis, proteins upregulated by Vpr ([Figure 3](#fig3){ref-type="fig"}A, right), which are all predicted to be secondary indirect effects, were distributed across multiple compartments. Furthermore, proteins depleted by Vpr were enriched (\>70%) for nucleic acid binding activity ([Figure 3](#fig3){ref-type="fig"}B, left). Vpr associates with DNA-binding proteins such as UNG via a substrate-binding surface that mimics DNA ([@bib92]). Thus, rather than targeting a small number of cellular proteins for degradation, Vpr may have a much wider range of direct targets, and the structure of the substrate binding surface suggests a possible mechanism for promiscuous recruitment of DNA- and RNA-binding cellular proteins.Figure 3Co-immunoprecipitation MS to Identify Direct Targets for Vpr-Mediated Degradation(A) Defined groups of Vpr-depleted and increased proteins were subject to gene ontology enrichment analysis and compared with a background of all proteins quantitated in these experiments. Gene Ontology (GO) cellular compartment enrichment analysis results were manually curated for 9 commonly used organelle level classifications, shown here. Bars shown in red with a + symbol were enriched compared with the expected number through chance, whereas bars in blue (−) were de-enriched. Where p \< 0.05, the associated p value represents the results of a Fisher's exact test with Bonferroni correction.(B) GO: molecular function analysis of the Vpr-depleted and -increased proteins, in this case showing all terms enriched within each group with p \< 0.05 in a Fisher's exact test with Bonferroni correction.(C) Graphical summary of the IP-MS experiment. All cells were stably transduced with a ShDCAF1 vector as described earlier. MLN4924 is a pan-Cullin inhibitor.(D) 20 most abundant proteins identified by coIP determined by number of unique peptides, normalized as a proportion of the maximum possible peptide count for each protein (exponentially modified protein abundance index \[emPAI\]). Proteins falling within the defined list of 302 Vpr-depleted and 413 Vpr-increased proteins are highlighted in blue and red, respectively.(E) The same 20 proteins with signal intensity rather than peptide count shown.(F) Pie chart indicating the overlap between the proteins co-immunoprecipitated with Vpr and the defined list of 302 Vpr-decreased (blue) and 413 Vpr-increased proteins (red) and proteins detected but falling into neither list (gray).(G) Bar chart showing the enrichment of Vpr-depleted and Vpr-increased proteins within proteins co-immunoprecipitated with Vpr compared with the expected numbers of proteins that would be co-immunoprecipitated from each group by chance. The p value was calculated by Fisher's exact test of a 2 × 2 contingency table (Vpr-depleted or -increased, identified by coIP or not identified).

To identify proteins targeted directly by Vpr, we first adopted a co-immunoprecipitation approach ([Figure 3](#fig3){ref-type="fig"}C). CEM-T4 T cells were transduced with a 3× hemagglutinin (HA)-tagged Vpr lentivirus in the presence of an shRNA to DCAF1 and the pan-cullin inhibitor MLN4924 to minimize substrate degradation and enhance co-immunoprecipitation. Factors specifically co-immunoprecipitated in the presence of Vpr are expected to include direct Vpr targets and, accordingly, were enriched for proteins depleted (rather than increased) in the presence of Vpr ([Figures 3](#fig3){ref-type="fig"}D--3G). However, the co-immunoprecipitation (coIP) was dominated by DCAF1, a stable binding partner of Vpr, identified with a signal intensity 2 orders of magnitude greater than that of all other proteins ([Figure 3](#fig3){ref-type="fig"}E). This is despite knockdown of DCAF1 in these cells, which reduces the DCAF1 protein abundance by approximately 50% ([Figure S2](#mmc1){ref-type="supplementary-material"}B). In addition, at least 13 proteins co-immunoprecipitating with Vpr here have been reported previously to physically interact with DCAF1 alone ([@bib11], [@bib26], [@bib29]), of which 11 are not regulated by Vpr, and two, CEP78 and IQGAP2, are upregulated by Vpr, explaining their presence in this list of proteins.

This mismatch between the high abundance of DCAF1 and the relatively low abundance of direct Vpr targets for degradation is consistent with previous reports that have also found that IP-MS based techniques are ideal for identification of the cellular machinery co-opted by viral proteins but often struggle to identify cellular targets that interact transiently and in competition with each other ([@bib36], [@bib50]). We therefore adopted an alternative approach, pulsed-stable isotope labeling with amino acids in cell culture (pulsed SILAC), to identify host proteins specifically destabilized within 6 h of exposure to Vpr ([Figure 4](#fig4){ref-type="fig"}A). This technique is directly analogous to a traditional pulse-chase experiment using radiolabeled methionine and/or cysteine but allows a global unbiased analysis of potential cellular targets ([@bib5]). Because proteins are fully labeled prior to exposure to Vpr, differences in abundance of labeled proteins between conditions exclusively reflect changes in protein degradation rates.Figure 4Pulsed SILAC Method to Identify Direct Targets for Vpr-Mediated Degradation(A) Graphical summary of the pulsed SILAC experiment.(B) Scatterplots showing the changes to protein stability of proteins after 6 or 24 h of exposure to a Vpr-bearing lentivirus compared with a control lentivirus, with previously defined groups of Vpr-depleted (blue) and -increased (red) proteins highlighted.(C) Expanded view of proteins degraded within 6 h of Vpr exposure. Significantly degraded (significance B \[Sig.B\] \< 0.01) proteins are highlighted in gold. The previously described Vpr targets HLTF, MUS81, and ZGPAT are shown in purple.

Six hours after exposure to Vpr, the stability of most proteins was unchanged ([Figure 4](#fig4){ref-type="fig"}B, top panel). However, a subset of proteins depleted by Vpr was already destabilized, consistent with Vpr-dependent proteasomal degradation. Therefore, these 27 proteins, including HLTF, represent direct targets for Vpr-mediated depletion ([Figure 4](#fig4){ref-type="fig"}C). After 24 h of exposure to Vpr, changes in protein stability reflected overall changes in protein abundance caused by Vpr in other experiments ([Figure 4](#fig4){ref-type="fig"}B, bottom panel), including proteins with increased as well as decreased stability. These changes are therefore indicative of both direct and indirect Vpr targets.

Combining all orthogonal approaches---whole cell proteomics to identify proteins depleted by Vpr in the context of viral infection or Vpr protein alone delivered in viral particles, MS coIP with epitope-tagged Vpr, and pulsed SILAC-based identification of proteins post-translationally degraded by Vpr---we identified at least 38 direct targets for Vpr-dependent degradation ([Table 1](#tbl1){ref-type="table"}). Vpr is both necessary and sufficient for depletion of these proteins, which are either bound by Vpr, or destabilized within 6 h of Vpr exposure (or both). In practice, this list very likely underestimates the true number of direct Vpr targets because several known targets of Vpr behaved appropriately but beyond the statistical cutoffs used to derive this table ([Table S2](#mmc1){ref-type="supplementary-material"}). [Table 1](#tbl1){ref-type="table"} is also limited to proteins expressed in the CEM-T4 T cell model, which excludes some known Vpr targets such as SMUG1 ([@bib75]). It should be noted that some cellular phenotypes for Vpr are exclusive to non-T cell targets, such as primary dendritic cells ([@bib60]) and macrophages ([@bib9], [@bib53]), and are unlikely to be explained by Vpr-mediated depletion of any of the proteins listed here.Table 1Direct Targets for Vpr-Mediated DegradationAccessionGenePreviously Confirmed Direct TargetPredicted from Temporal Profile[a](#tblfn1){ref-type="table-fn"}Vpr NecessaryIncoming Vpr SufficientDegraded within 6 hCoIP([Figure 1](#fig1){ref-type="fig"})([Figure 2](#fig2){ref-type="fig"})([Figure 4](#fig4){ref-type="fig"})([Figure 3](#fig3){ref-type="fig"})[Q56NI9](ncbi-p:Q56NI9){#intref0155}ESCO2----yesyesNDyes[Q16637](ncbi-p:Q16637){#intref0160}SMN1 / SMN2--yesyesyesNSyes[Q14527](ncbi-p:Q14527){#intref0165}HLTFyes[b](#tblfn2){ref-type="table-fn"}yesyesyesyes--[Q96KM6](ncbi-p:Q96KM6){#intref0170}ZNF512B----yesyesyes--[Q8WY36](ncbi-p:Q8WY36){#intref0175}BBX----yesyesyesyesA6NFI3ZNF316----yesyesyes--[Q8NI77](ncbi-p:Q8NI77){#intref0180}KIF18A----yesyesNDyes[Q8TF76](ncbi-p:Q8TF76){#intref0185}HASPIN----yesyesyes--[Q9Y4B6](ncbi-p:Q9Y4B6){#intref0190}VPRBPyes[c](#tblfn3){ref-type="table-fn"}--yesyesNSyes[Q96FF9](ncbi-p:Q96FF9){#intref0195}CDCA5--yesyesyesyes--[Q6PK04](ncbi-p:Q6PK04){#intref0200}CCDC137--yesyesyesyes--[Q9NXE8](ncbi-p:Q9NXE8){#intref0205}CWC25----yesyesyes--[Q86Y91](ncbi-p:Q86Y91){#intref0210}KIF18B--yesyesyesyes--[Q6P4F7](ncbi-p:Q6P4F7){#intref0215}ARHGAP11A----yesyesyes--[Q6NW34](ncbi-p:Q6NW34){#intref0220}NEPRO----yesyesyes--[Q9BVJ6](ncbi-p:Q9BVJ6){#intref0225}UTP14A----yesyesyes--[Q9NVN8](ncbi-p:Q9NVN8){#intref0230}GNL3L--yesyesyesyes--[Q5QJE6](ncbi-p:Q5QJE6){#intref0235}DNTTIP2----yesyesyes--[Q69YH5](ncbi-p:Q69YH5){#intref0240}CDCA2----yesyesyes--[Q96BK5](ncbi-p:Q96BK5){#intref0245}PINX1----yesyesyes--[Q8N5A5](ncbi-p:Q8N5A5){#intref0250}ZGPATyes[d](#tblfn4){ref-type="table-fn"}--yesyesyes--[Q13823](ncbi-p:Q13823){#intref0255}GNL2----yesyesyes--[Q9UHI6](ncbi-p:Q9UHI6){#intref0260}DDX20----yesyesNSyes[Q96ME7](ncbi-p:Q96ME7){#intref0265}ZNF512----yesyesyes--[Q14586](ncbi-p:Q14586){#intref0270}ZNF267----yesyesNSyes[Q9H8V3](ncbi-p:Q9H8V3){#intref0275}ECT2----yesyesyes--[P57678](ncbi-p:P57678){#intref0280}GEMIN4----yesyesNSyes[P52701](ncbi-p:P52701){#intref0285}MSH6----yesyesNSyes[O75190](ncbi-p:O75190){#intref0290}DNAJB6----yesyesyes--[Q96NY9](ncbi-p:Q96NY9){#intref0295}MUS81yes[e](#tblfn5){ref-type="table-fn"}--yesyesyes--[O60563](ncbi-p:O60563){#intref0300}CCNT1----yesyesyes--[Q9P031](ncbi-p:Q9P031){#intref0305}CCDC59----yesyesyes--[Q9UIS9](ncbi-p:Q9UIS9){#intref0310}MBD1----yesyesNSyes[Q9UMY1](ncbi-p:Q9UMY1){#intref0315}NOL7----yesyesyes--[Q6ZN55](ncbi-p:Q6ZN55){#intref0320}ZNF574----yesyesNSyes[Q9BXS6](ncbi-p:Q9BXS6){#intref0325}NUSAP1----yesyesyes--[O95235](ncbi-p:O95235){#intref0330}KIF20A----yesyesyes--[P35251](ncbi-p:P35251){#intref0335}RFC1----yesyesNSyes[^3][^4][^5][^6][^7][^8]

The Direct Vpr Targets SMN1, CDCA2, and ZNF267 Contribute to G2/M Cell Cycle Arrest {#sec2.5}
-----------------------------------------------------------------------------------

Several cellular phenotypes have been described for Vpr, including G2/M arrest, transactivation of the HIV long terminal repeat (LTR), and modulation of cellular signaling pathways such as NFκB and NFAT arrest ([@bib6], [@bib25], [@bib28], [@bib47], [@bib49], [@bib62], [@bib71]). The mechanisms responsible for these phenotypes are controversial. Wide-scale proteome remodeling by Vpr and direct targeting of multiple proteins suggest a model in which Vpr interacts with diverse cellular proteins and pathways, resulting in cumulative or redundant effects on cellular phenotypes. This model does not contradict any single mechanism but suggests that several are involved, with potential variability between different cell types and experimental systems.

To test our model, we investigated the best-described phenotype for Vpr, cell cycle arrest at the G2/M phase. We hypothesized that differential depletion of cellular proteins by different Vpr mutants tested in [Figure 2](#fig2){ref-type="fig"}, which displayed a spectrum of capacity to cause G2/M arrest, would highlight proteins whose depletion results in this cellular phenotype. We first examined proteins with a published connection to Vpr-mediated G2/M arrest: MCM10, MUS81, and EME1. MCM10 has been reported to be directly degraded by Vpr, resulting in cell cycle arrest ([@bib72]). Vpr-mediated depletion of MUS81 and EME1 has been proposed to be a consequence of Vpr interaction with SLX4 ([@bib41]), another proposed mechanism of Vpr-mediated G2/M arrest, although this is controversial ([@bib4], [@bib21], [@bib96]). In our system, of these three proteins (MCM10, MUS81, and EME1), only depletion of MCM10 showed a strong correlation with the extent of G2/M arrest caused by the different mutants ([Figure 5](#fig5){ref-type="fig"}A). As described previously ([@bib72]), depletion of MCM10 by RNAi was sufficient to cause accumulation of CEM-T4 T cells at G2/M ([Figures 5](#fig5){ref-type="fig"}B and 5C).Figure 5Direct Vpr Targets Involved in G2/M Arrest(A) Correlation between depletion of MCM10, MUS81, and EME1 by each Vpr mutant tested in the experiment shown in [Figure 2](#fig2){ref-type="fig"} and the extent of G2/M arrest caused by that mutant. The red line shows linear regression analysis.(B) Example DNA staining showing G2/M arrest caused by shRNA-mediated depletion of MCM10, representative of three independent experiments. Watson pragmatic modeling was used to identify cells in G1 (blue), S (gray), or G2/M (red) phase.(C) Real-time qRT-PCR analysis of MCM10 mRNA abundance in cells transduced with control or MCM10-targeting shRNA. Values were generated using the ΔΔCT method relative to GAPDH mRNA abundance and normalized to the control condition. Bars show mean and SEM of three technical replicates.(D) Targeted shRNA screen of direct Vpr target proteins identified here whose depletion correlated with G2/M arrest in the experiment detailed in [Figure 2](#fig2){ref-type="fig"}. Bars show means and SEM of at least two replicates from more than three independent experiments. Dashed lines show control average ± 3 SDs. The control condition contains combined data from three different control shRNAs.(E) Real-time qRT-PCR analysis of mRNA abundance in cells transduced with control or targeting shRNA. Values were generated using the ΔΔCT method relative to GAPDH mRNA abundance and normalized to the control condition. Bars show mean and SEM of three technical replicates.(F) Correlation between depletion of SMN1, CDCA2, and ZNF267 by each Vpr mutant tested in the experiment shown in [Figure 2](#fig2){ref-type="fig"} and the extent of G2/M arrest caused by that mutant.(G) Example DNA staining showing G2/M arrest caused by shRNA-mediated depletion of SMN1, CDCA2, and ZNF267 using a second independent shRNA; representative of at least two independent experiments.

We therefore interrogated our Vpr mutant dataset ([Figure 2](#fig2){ref-type="fig"}) for other direct Vpr targets ([Table 1](#tbl1){ref-type="table"}) that, like MCM10, correlated with the extent of G2/M arrest. In total, we identified 14 targets with a significant relationship (p \< 0.05 in a linear regression analysis) ([Figure 5](#fig5){ref-type="fig"}D). Next we tested whether shRNA-mediated depletion could phenocopy Vpr-dependent cell cycle arrest at G2/M ([Figure 5](#fig5){ref-type="fig"}D). Depletion of 3 Vpr targets (SMN1, CDCA2, and ZNF267) caused G2/M arrest ([Figures 5](#fig5){ref-type="fig"}D and 5E). The correlation between G2/M arrest and depletion of these three proteins by Vpr mutants is shown in [Figure 5](#fig5){ref-type="fig"}F. The phenotype resulting from RNAi protein depletion was confirmed with a second shRNA ([Figure 5](#fig5){ref-type="fig"}G). Thus, several Vpr targets contribute independently to G2/M cell cycle arrest, consistent with a model whereby depletion of multiple cellular proteins underpins the various phenotypes associated with Vpr expression.

Some Vpr Targets Are Conserved across Primate Lentiviruses, but Global Cellular Proteome Remodeling Is Unique to the HIV-1/SIVcpz Lineage {#sec2.6}
-----------------------------------------------------------------------------------------------------------------------------------------

Targeting of key cellular proteins such as BST2 or the APOBEC3 family is conserved across multiple lentiviral lineages, demonstrating the *in vivo* selective advantage of these interactions. We therefore tested a diverse panel of lentiviral Vpr proteins to determine whether they share activity with the NL4-3 Vpr variant used in all of the experiments above. We included Vpr variants from primary isolates of HIV-1 from two distinct cross-species transmissions from apes to humans (group M and group O), in addition to a closely related variant from Simian immunodeficiency virus (SIV) of chimpanzees (SIVcpz). We also tested Vpr variants from divergent primate lineages, including HIV-2, and SIVs from sooty mangabeys (SIVsmm), African green monkeys (SIVagm), and red-capped mangabeys (SIVrcm) ([Figures 6](#fig6){ref-type="fig"}A--6C). In addition to Vpr, which is present in all primate lentiviruses, viruses of some lineages also bear Vpx, a gene duplication of Vpr. Because depletion of some substrates and cellular functions switches between Vpr and Vpx in lineages encoding this accessory gene ([@bib18], [@bib48]), we also included a Vpx variant from HIV-2.Figure 6Identification of Proteome Changes Conserved Between Human and Primate Lentiviral Vpr Lineages(A) Graphical summary of the TMT experiment testing conservation of Vpr function.(B) GFP+ (transduced) cells at harvest. Cells were transduced at an infectious MOI of 1.5 based on prior titration, with the actual resulting percent transduction varying slightly across the samples. Because non-HIV-1/SIVcpz Vpr is not packaged in the viral particles used, the percent transduced represents all cells exposed to Vpr under those conditions.(C) Proportion of cells in G2/M at point of harvest, based on 7-AAD staining and Watson pragmatic modeling.(D) Scatterplots showing the pairwise comparison between each Vpr tested and empty vector control, with defined groups of 302 Vpr-depleted (blue) and 413 increased (red) proteins highlighted.(E) Immunoblot of example known, non-conserved, and conserved targets of Vpr-mediated depletion. The HIV-2 Vpr is a primary isolate HIV-2 Vpr (7312a), whereas the proteomics experiment described in (A) used HIV-2 ROD Vpr.

Extensive Vpr-dependent remodeling of the cellular proteome was conserved across the HIV-1/SIVcpz lineage ([Figure 6](#fig6){ref-type="fig"}D, top row). Although Vpr variants from other lineages showed a narrower set of changes, depletion of some proteins, particularly those most heavily depleted by HIV-1 Vpr, was conserved across multiple lineages ([Table 2](#tbl2){ref-type="table"}). Depletion of selected proteins for which commercial antibody reagents were available was readily confirmed by immunoblot of cells transduced with an overlapping panel of Vpr variants ([Figure 6](#fig6){ref-type="fig"}E). These conserved targets of direct Vpr-mediated degradation are likely to provide an *in vivo* replicative advantage for all primate lentiviruses. Although the failure of SIVrcm, SIVagm, or SIVsmm Vpr variants to degrade proteins that are targeted by HIV-1/SIVcpz may be due to the use of human rather than cognate primate cells, it is notable that HIV-2 Vpr did not cause global proteome remodeling, despite being tested in the host cell to which it is adapted.Table 2Proteins Depleted by Vpr Variants from Multiple LineagesAccessionGene NameDirect TargetLineages Showing Profound Depletion[a](#tblfn6){ref-type="table-fn"}Profound Depletion by Number of Tested Vpr Variants within Each LineageHIV-1/SIVcpzSIVrcmSIVsmm/HIV-2SIVagm[Q86Y91](ncbi-p:Q86Y91){#intref0340}KIF18Byes44/41/11/21/1[Q8NI77](ncbi-p:Q8NI77){#intref0345}KIF18Ayes44/41/12/21/1[Q14865](ncbi-p:Q14865){#intref0350}ARID5B--44/41/12/21/1[P46013](ncbi-p:P46013){#intref0355}MKI67--42/41/12/21/1[Q56NI9](ncbi-p:Q56NI9){#intref0360}ESCO2yes34/40/12/21/1[Q6P4F7](ncbi-p:Q6P4F7){#intref0365}ARHGAP11Ayes34/40/11/21/1[Q96KM6](ncbi-p:Q96KM6){#intref0370}ZNF512Byes34/40/12/21/1[Q9Y4B6](ncbi-p:Q9Y4B6){#intref0375}DCAF1yes34/40/12/21/1[Q6NW34](ncbi-p:Q6NW34){#intref0380}NEPROyes34/41/12/20/1[Q8N3Z6](ncbi-p:Q8N3Z6){#intref0385}ZCCHC7--33/40/11/21/1[Q8NDF8](ncbi-p:Q8NDF8){#intref0390}PAPD5--32/40/11/21/1[Q8TF76](ncbi-p:Q8TF76){#intref0395}HASPINyes24/40/10/21/1[Q9NXE8](ncbi-p:Q9NXE8){#intref0400}CWC25yes24/40/10/21/1[Q96BK5](ncbi-p:Q96BK5){#intref0405}PINX1yes24/40/11/20/1[Q9NVN8](ncbi-p:Q9NVN8){#intref0410}GNL3Lyes23/41/10/20/1[Q6ZN06](ncbi-p:Q6ZN06){#intref0415}ZNF813--24/41/10/20/1[Q9NW13](ncbi-p:Q9NW13){#intref0420}RBM28--23/40/11/20/1[Q6W2J9](ncbi-p:Q6W2J9){#intref0425}BCOR--24/40/10/21/1[^9]

Although none of the identified HIV-1 Vpr targets were degraded by the HIV-2 Vpx (HIV-2~ROD~) tested, we noted a shared ability of HIV-2 Vpx and SIVagm Vpr to deplete TASOR, a critical component of the human silencing hub (HuSH) transcription repressor complex ([@bib82]; [Figure 7](#fig7){ref-type="fig"}A). While this manuscript was in preparation, two other groups independently discovered and reported Vpx-mediated depletion of TASOR ([@bib8], [@bib93]). The HuSH complex mediates position-dependent transcriptional repression of a subset of lentiviral integrations, and we showed previously that antagonism of HuSH is able to potentiate HIV reactivation in the J-LAT model of latency ([@bib82]). As predicted, Vpx phenocopied the effect of RNAi-mediated TASOR depletion on reactivation of the HuSH-sensitive J-LAT clone A1 ([Figure 7](#fig7){ref-type="fig"}B).Figure 7Shared Targets of Lentiviral Vpr and Vpx Proteins(A) Scatterplots showing pairwise comparison between each Vpr tested and empty vector control, with HuSH complex components highlighted.(B) Bar graph of the percentage of GFP-positive JLAT-A1 cells after transduction with control (Cre recombinase), Vpr, or Vpx proteins and treatment with tumor necrosis factor alpha (TNF-α). Mean and SEM of 3 biological replicates per condition are shown, representative of three independent similar experiments. The p values were determined by ordinary one-way ANOVA with Bonferroni comparison between Vpr/Vpx treatment and control-treated cells.(C) Phylogenetic tree of primate lentiviruses based on an alignment of Vpr nucleic acid sequences, with 5 major lineages of primate lentiviruses labeled. Information regarding Vpr and Vpx activity is based on a selected number of isolates tested in each lineage ([@bib48]).(D) Immunoblot of TASOR in cells transduced with a panel of Vpx and Vpr proteins.(E) Graphical summary of the TMT experiment to examine proteome changes in cells transduced with HIV-2 Vpr and Vpx for an extended period.(F) Scatterplots displaying pairwise comparison between cells transduced with 7312a HIV-2 Vpr and Vpx for 96 h compared with those transduced with an empty vector for 96 h. Blue and red dots represent the defined groups or proteins depleted or increased by NL4-3 Vpr, respectively. Points ringed in gold indicate the direct targets of NL4-3 Vpr-mediated degradation listed in [Table 1](#tbl1){ref-type="table"}.

Previous reports ([@bib8], [@bib93]) were conflicted regarding the conservation of TASOR depletion across Vpr variants. With some exceptions, most primate lentiviruses can be categorized into 5 lineages ([Figure 7](#fig7){ref-type="fig"}C), two of which encode Vpx. The previously described canonical function of Vpx is degradation of SAMHD1 ([@bib31], [@bib40]). Two lentiviral lineages lack Vpx but use Vpr to degrade SAMHD1, whereas the HIV-1/SIVcpz lineage lacks SAMHD1 antagonism ([@bib48]). We considered that TASOR antagonism may follow the same pattern and thus tested Vpx proteins from both Vpx-bearing lineages and representative Vpr variants from lineages that use Vpr to degrade SAMHD1. All of these proteins were able to deplete TASOR in Vpx/Vpr-transduced cells ([Figure 7](#fig7){ref-type="fig"}D), and, therefore, antagonism of SAMHD1 and TASOR appears to follow the same pattern.

Although the targeting of some substrates was conserved across Vpr variants from multiple lineages, we did not observe broad proteome remodeling outside of the HIV-1/SIVcpz lineage. However, in the experiment described in [Figure 6](#fig6){ref-type="fig"}A, an HIV-1-based lentiviral transduction system was used. Of the Vpr and Vpx variants tested, only Vpr proteins from the HIV-1/SIVcpz alleles are efficiently packaged into the virion. In these cases, cells receive both incoming and *de novo*-synthesized Vpr, whereas, in the case of other variants tested, only *de novo*-synthesized Vpr is present. Therefore, there is a time lag of 18--24 h for viral entry, reverse transcription, integration, and *de novo* synthesis of protein to begin. The more limited proteome remodeling seen in Vpr variants could reflect a lack of time for such changes to occur.

To account for this, we carried out an experiment in which cells were transduced with Vpr or Vpx from the primary HIV-2 isolate 7312a and assayed 48--96 h post-transduction ([Figure 7](#fig7){ref-type="fig"}E), allowing time for additional changes to develop after *de novo* Vpr/Vpx synthesis. Even 96 h after transduction, HIV-2 Vpr showed very limited changes. The majority of these changes consisted of depletion of proteins also targeted by HIV-1 Vpr ([Figure 7](#fig7){ref-type="fig"}F, left panel). Curiously, 7312a HIV-2 Vpx also depleted several proteins modulated by HIV-1 Vpr ([Figure 7](#fig7){ref-type="fig"}F, right panel), including direct targets for HIV-1 Vpr-mediated degradation, BBX, HASPIN, and ARHGAP11A. Some proteins were degraded by both HIV-2 Vpr and Vpx, whereas others were only degraded by the Vpx of this isolate. In lentiviral strains and/or lineages that encode both Vpr and Vpx, the responsibility for degrading certain targets of HIV-1 Vpr is therefore shared between Vpr and Vpx, further emphasizing their *in vivo* importance.

Conversely, global proteome remodeling does not occur from extended expression of HIV-2 Vpr or Vpx. The difference between HIV-1 and HIV-2 Vpr in this respect may contribute, in part, to the increased pathogenicity of HIV-1 in humans over HIV-2 ([@bib35]), particularly given the potential for HIV-1 Vpr to drive these changes in Vpr-exposed but uninfected bystander cells.

Discussion {#sec3}
==========

Proteomics analyses of cells infected with viruses from different orders have revealed widespread and varied changes to the cellular proteome ([@bib14], [@bib15], [@bib23], [@bib91]). Although these changes are presumed to be multifactorial, in the case of HIV-1 infection, our data show that the majority of changes can be attributed to the action of a single viral protein, Vpr. We propose that this global cellular proteome remodeling consists of direct targeting of multiple cellular proteins for proteasomal degradation via the DCAF1/DDB1/CUL4A E3 ligase complex, followed by resulting secondary effects on other proteins. Although many of the changes caused by Vpr are secondary, they occur within the physiological time frame of productive infection ([@bib61], [@bib65]) and are therefore relevant to our understanding of the HIV-1-infected cell. Further, we have recently mapped changes to the cellular proteome in HIV-1-infected primary human CD4+ T cells and confirmed that the Vpr-mediated changes described here in CEM-T4s are recapitulated in the natural cell type of HIV infection ([@bib63]).

Before this study, the list of direct Vpr targets was already extensive. Here we confirmed Vpr-mediated depletion of the previously described Vpr targets HLTF ([@bib32], [@bib42]), ZGPAT ([@bib57]), MCM10 ([@bib72]), UNG2 ([@bib75]), TET2 ([@bib51]), and MUS81 and EME1 ([@bib41], [@bib96]), whereas SMUG1 ([@bib75]) and PHF13 ([@bib27]) were not detected in our model T cell line. By analogy with other HIV accessory proteins, it might have been predicted that this list of Vpr targets would be nearly complete. Instead, we show here that it is only the tip of the iceberg.

Although surprising, the ability of Vpr to degrade multiple cellular factors may be explained by the biology of this small protein. Mechanistically, depletion of multiple proteins with nucleic acid binding properties is consistent with known structural determinants of Vpr substrate recruitment. From a functional viewpoint, although HIV-1 has three accessory proteins (Vpu, Nef, and Vif) to aid viral replication and counteract host defenses in the late stages of the viral replication cycle, Vpr is the only HIV-1 accessory protein packaged into virions. Multiple targets may therefore be required to protect incoming virions from cellular factors and to prime newly infected cells for productive viral replication.

This work is not the first attempt to use unbiased proteomics analysis to characterize Vpr function. Previous studies have used single proteomics experiments or methods to identify candidate proteins that either interact with or are depleted by Vpr, with individual proteins followed up using targeted immunoreagents. For example, Vpr binding partners were identified by [@bib36] and [@bib32] using IP-MS. [@bib36] did not determine whether any of these proteins were depleted, whereas [@bib32] focused on the single target protein, HLTF and found it to be depleted by Vpr. Similarly, [@bib42] used a SILAC-based approach to quantify proteomic changes in cells exposed to viral particles bearing Vpr, identifying 8 proteins that were depleted by at least 20%. Of these, only one, HLTF, was confirmed to be a direct Vpr target by targeted orthogonal approaches.

As expected, the lists of "candidate" Vpr proteins identified but not pursued in the above studies overlaps with this work, and, in some instances, we confirmed these candidates to be direct targets for Vpr-mediated degradation. For example, SMN1 was found to bind Vpr by [@bib36] and to be degraded by Vpr by [@bib42] in independent proteomics experiments. Similarly, ESCO2 was found to bind Vpr by [@bib32], but the depletion was not confirmed by immunoblot, most likely because of poor performance of the commercial antibody used. We have shown here that both of these proteins are direct targets for Vpr-mediated degradation.

In contrast to previous studies, rather than using a targeted approach to follow up only a small number of potential Vpr targets, we combined complementary proteomics analyses to describe the global proteome remodeling caused by Vpr and multiple direct substrates for Vpr-mediated depletion. The two established criteria for Vpr targets (binding and destabilization) are satisfied by numerous proteins identified here, including ESCO2, SMN1, BBX, and KIF18A. These proteins are therefore not candidate Vpr targets, but *bona fide* Vpr targets, proven to the same standard of evidence as other, previously described substrates.

However, in our proposed model, Vpr binds and degrades multiple cellular proteins, with the total pool of Vpr shared over multiple targets. Therefore, identification of cellular targets by coIP is technically problematic and more prone to false negatives compared with other proteins that establish interactions with a small number of binding partners. We therefore used an alternative method of identifying direct targets for Vpr-mediated depletion: proteins that are post-translationally degraded within 6 h of treatment with Vpr. We are confident that the other proteins identified in this fashion also represent direct targets for Vpr-mediated degradation because secondary effects are excluded by both intrinsic elements of the technique and the short time frame allowed.

Despite the importance of Vpr *in vivo*, a positive *in vitro* viral replication phenotype is often absent in T cell infection models ([@bib22], [@bib24]). Nonetheless, expression of Vpr in T cells causes cell cycle arrest ([@bib6], [@bib25], [@bib71]); cell death ([@bib6]); transactivation of the viral LTR ([@bib25]); enhancement or antagonism of crucial signaling pathways, including NFAT ([@bib28]) and NF-κB ([@bib47], [@bib49], [@bib62]); disruption of PARP1 localization ([@bib28], [@bib62]); defects in chromatid cohesion ([@bib78]); and induction of the DNA damage response ([@bib70], [@bib88]). At least some of these phenotypes can be segregated ([@bib6], [@bib28]). The molecular mechanisms underpinning these phenomena have remained controversial. In our model, these multiple phenotypes can be explained by Vpr targeting multiple cellular proteins and pathways with potential for redundant or cumulative effects.

Here we considered the most well-described cellular phenotype for Vpr, G2/M cell cycle arrest, with findings compatible with this model. In addition to confirming the previously described effect of Vpr-mediated MCM10 degradation, we identified three other proteins that are directly targeted by Vpr, show depletion correlating with the extent of G2/M-mediated arrest in a panel of Vpr mutants, and result in arrest at G2/M when depleted through RNAi. Notably, depletion of two of these proteins, SMN1 and CDCA2 (Repo-Man), has been shown to activate the DNA damage response and stimulate ATM and/or ATR kinase activity ([@bib39], [@bib64]), a critical step toward G2/M arrest caused by Vpr ([@bib4], [@bib21], [@bib73]). The contribution of multiple Vpr targets to the same cellular phenotype may also be exemplified by another described cellular phenotype for Vpr, premature chromatid segregation (PCS) ([@bib78]). Although not specifically investigated here, RNAi-mediated knockdown of three proteins depleted by Vpr---ESCO2, CDCA5 (Sororin), and HASPIN---has been associated previously with this phenotype in different systems ([@bib12], [@bib30], [@bib68]).

In conclusion, Vpr degrades multiple cellular targets, resulting in global remodeling of the host proteome and labyrinthine changes to different cellular pathways. This explains why its effects on cellular phenotypes and viral replication are complex and remain poorly understood, why the functional consequences of individual Vpr targets identified and studied in isolation have proved elusive, and why the search for a single critical Vpr target has been problematic.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Rabbit anti-TASORAtlas AntibodiesCat\#HPA006735; RRID: [AB_1852384](nif-antibody:AB_1852384){#interref430}Rabbit anti-BBXBethyl LaboratoriesCat\#A303-151A; RRID: [AB_10893371](nif-antibody:AB_10893371){#interref435}Rabbit anti-HLTFBethyl LaboratoriesCat\#A300-230A; RRID: [AB_2117307](nif-antibody:AB_2117307){#interref440}Rabbit anti-RALYBethyl LaboratoriesCat\#A302-070A; RRID: [AB_1604220](nif-antibody:AB_1604220){#interref445}Rabbit anti-ZNF512BBethyl LaboratoriesCat\#A303-234A; RRID: [AB_10952552](nif-antibody:AB_10952552){#interref450}Mouse anti-SMN1/2Cell Signaling TechnologyCat\#12976S; RRID: [AB_2798076](nif-antibody:AB_2798076){#interref455}Rabbit anti-ESCO2Novus BiologicalsCat\#NB100-87021; RRID: [AB_1201179](nif-antibody:AB_1201179){#interref460}Mouse anti-UNG2OrigeneCat\#TA503563; RRID: [AB_11126624](nif-antibody:AB_11126624){#interref465}Rabbit anti-VprProteintechCat\#51143-I-AP;RRID: [AB_10695191](nif-antibody:AB_10695191){#interref470}Mouse anti-CCNB1Santa CruzCat\#SC-245; RRID: [AB_627338](nif-antibody:AB_627338){#interref475}Mouse anti-ZGPATSanta CruzCat\#SC-515524Mouse anti-β-actinSigma-AldrichCat\#A5316; RRID: [AB_476743](nif-antibody:AB_476743){#interref480}Mouse anti-p24AbcamCat\#ab9071; RRID: [AB_306981](nif-antibody:AB_306981){#interref485}Mouse anti-VCPAbcamCat\#ab11433; RRID: [AB_298039](nif-antibody:AB_298039){#interref490}Goat anti-mouse HRPJackson ImmunoResearchCat\#115-035-146; RRID: [AB_2307392](nif-antibody:AB_2307392){#interref495}Goat anti-rabbit HRPJackson ImmunoResearchCat\#111-035-144; RRID: [AB_2307391](nif-antibody:AB_2307391){#interref500}Mouse anti-CD4-AF647BiolegendCat\#317422; RRID: [AB_571941](nif-antibody:AB_571941){#interref505}Mouse anti-CD271(NGFR)-APCBiolegendCat\#345107; RRID: [AB_10639737](nif-antibody:AB_10639737){#interref510}**Chemicals, Peptides, and Recombinant Proteins**Sigma EZview Red Anti-HA Affinity GelSigma-AldrichCat\#E6779IgG-SepharoseGE HealthcareCat\#17096901IGEPAL CA-630 (NP-40)Sigma-AldrichCat\#I3021BenzonaseSigma-AldrichCat\#E1014MLN4924MilliporeCat\#5054770001Zidovudine (AZT)NIH AIDS Reagent ProgramCat\#3485EfavirenzNIH AIDS Reagent ProgramCat\#46247-AADStratechCat\#17501-AATTNFαPeproTech, 300-01ACat\#300-01AR10 ArginineCambridge Isotope LaboratoriesCat\#CNLM-539R6 ArginineCambridge Isotope LaboratoriesCat\#CLM-2265K8 LysineCambridge Isotope LaboratoriesCat\#CNLM-291K4 LysineCambridge Isotope LaboratoriesCat\#DLM-2640TMT10plex Isobaric Label ReagentThermo Fisher ScientificCat\#90110TMT11-131C Isobaric Label ReagentThermo Fisher ScientificCat\#A34807PreOmics-IST NHS Sample preparation kitPreOmicsCat\#P.O.00030SpeedBead Carboxylate modified magnetic particlesGE HealthcareCat\#45152105050250SpeedBead Carboxylate modified magnetic particlesGE HealthcareCat\#65152105050250Trypsin, Mass Spectrometry GradeThermo Fisher ScientificCat\#90057**Deposited Data**Raw proteomics dataThis paperPRIDE: [PXD013221](pride:PXD013221){#intref0010}UniProt Human reference proteome (26/09/2017)Uniprot ([@bib86])<https://www.uniprot.org>trEMBL (Human) sequence database (26/09/2017)Uniprot ([@bib86])<https://www.uniprot.org>GO Ontology database (06/09/2018)Gene Ontology Consortium ([@bib84])Accessed through <http://www.pantherdb.org>CRAPome v1.1([@bib58])<http://www.crapome.org/>**Experimental Models: Cell Lines**CEM-T4NIH AIDS Reagent Program, Dr JP Jacobs ([@bib19]),Cat\#117J-Lat Tat-GFP Cells (A1)NIH AIDS Reagent Program, Dr E Verdin ([@bib38], [@bib37])Cat\#9852HEK293TLehner Lab stockRRID:CVCL_0063**Oligonucleotides**MCM10_FOR 5′-CTTATACAGAAGAGGCTGATG-3′Sigma-AldrichKiCqStart: H_MCM10_1MCM10_REV 5′-CCTCTTGCAACTCTTCATTC-3′Sigma-AldrichKiCqStart: H_MCM10_1ZNF267_FOR 5′-GTAGAATTCTCTTTGGAGGAGSigma-AldrichKiCqStart: H_ZNF267_1ZNF267_REV 5′-CTCACTCTTCACATTCCAAGSigma-AldrichKiCqStart: H_ZNF267_1CDCA2_FOR 5′-AGGAAAGTCATCATCCTACCSigma-AldrichKiCqStart: H_CDCA2_1CDCA2_REV 5′-GATGGTTTGTTTCAGGAGAG-3Sigma-AldrichKiCqStart: H_CDCA2_1SMN1_FOR 5′-GGAAAGCCAGGTCTAAAATTC-3Sigma-AldrichKiCqStart: H_SMN1_1SMN1_REV 5′-AGAATCTGGACATATGGGAG-3Sigma-AldrichKiCqStart: H_SMN1_1GAPDH_FOR 5′ ATGGGGAAGGTGAAGGTCG-3[@bib7]N/AGAPDH_REV 5- CTCCACGACGTACTCAGCG-3[@bib7]N/A**Recombinant DNA**pNL4-3-dE-EGFPNIH AIDS Reagent Program, Drs Haili Zhang, Yan Zhou, and Robert Siliciano ([@bib94])Cat\#11100pNL4-3-dE-EGFP-dVprThis paperN/ApHRSIN RSV NL4.3 Vpr Ub EmeraldThis paperN/ApHRSIN RSV NL4.3 Vpr S79A Ub EmeraldThis paperN/ApHRSIN RSV NL4.3 Vpr Q65R Ub EmeraldThis paperN/ApHRSIN RSV NL4.3 Vpr E24R R36P Ub EmeraldThis paperN/ApHRSIN RSV NL4.3 Vpr W54R Ub EmeraldThis paperN/ApHRSIN RSV NL4.3 Vpr Y47A, D52A, W54R Ub EmeraldThis paperN/ApHRSIN RSV NL4.3 HA-Vpr Ub EmeraldThis paperN/ApHRSIN RSV NL4.3 3xHA-Vpr Ub EmeraldThis paperN/ApHRSIN RSV 98BR004 HA-Vpr Ub EmeraldThis paperN/A, but based on Vpr sequence GenBank: [AAK31002.1](ncbi-p:AAK31002.1){#intref0035}pHRSIN RSV BCF09 HA-Vpr Ub EmeraldThis paperN/A, but based on Vpr sequence GenBank: [CAA75954.1](ncbi-p:CAA75954.1){#intref0040}pHRSIN RSV SIVcpzPtt MB897 HA-Vpr Ub EmeraldThis paperN/A, but based on Vpr sequence GenBank: [ABU53019.1](ncbi-p:ABU53019.1){#intref0045}pHRSIN RSV SIVrcm 02CM8081 HA-Vpr Ub EmeraldThis paperN/A, but based on Vpr sequence GenBank: [ADK78264.1](ncbi-p:ADK78264.1){#intref0050}pHRSIN RSV SIVagm Sab92018 HA-Vpr Ub EmeraldThis paperN/A, but based on Vpr sequence GenBank: [ADO34202.1](ncbi-p:ADO34202.1){#intref0055}pHRSIN RSV SIVsmm E660 HA-Vpr Ub EmeraldThis paperN/A, but based on Vpr sequence GenBank: [ANT86736.1](ncbi-p:ANT86736.1){#intref0060}pHRSIN RSV HIV-2 ROD HA-Vpr Ub EmeraldThis paperN/A, but based on Vpr sequence GenBank: [CAA28911.1](ncbi-p:CAA28911.1){#intref0065}pHRSIN RSV HIV-2 7312a HA-Vpr Ub EmeraldThis paperN/A, but based on Vpr sequence GenBank: [AAL31354.1](ncbi-p:AAL31354.1){#intref0070}pHRSIN RSV SIVmus 01CM1239 HA-Vpr Ub EmeraldThis paperN/A, but based on Vpr sequence GenBank: [ABO61047.1](ncbi-p:ABO61047.1){#intref0075}pHRSIN RSV HIV-2 Rod HA-Vpx Ub EmeraldThis paperN/A, but based on Vpx sequence GenBank: [AAB00766.1](ncbi-p:AAB00766.1){#intref0080}pHRSIN RSV HIV-2 7312a HA-Vpx Ub EmeraldThis paperN/A, but based on Vpx sequence GenBank: [AAL31353.1](ncbi-p:AAL31353.1){#intref0085}pHRSIN RSV SIVrcm NG411 HA-Vpx Ub EmeraldThis paperN/A, but based on Vpx sequence GenBank: [AAK69676.1](ncbi-p:AAK69676.1){#intref0090}pHRSIN RSV SIVmnd-2 5440 HA-Vpx Ub EmeraldThis paperN/A, but based on Vpx sequence GenBank: [AAO22477.1](ncbi-p:AAO22477.1){#intref0095}pC.SIREN.puro shControl 1 (GTTATAGGCTCGCAAAAGG)This paperN/ApC.SIREN.puro shControl 2 (GTAAGGCTATGAAGAGATAC)This paperN/ApC.SIREN.puro shControl 3 (ACTACCGTTGTTATAGGTG)This paperN/ApC.SIREN.hygro *DCAF1* (GCTGAGAATACTCTTCAAGAA)This paperN/ApC.SIREN.puro sh*MCM10*-1 (AGATGCAGGAGCGCTACTTTG)This paperN/ApC.SIREN.puro sh*MCM10*-2 (GACGGCGACGGTGAATCTTAT)This paperN/ApC.SIREN.puro sh*CCNT1* (GCCTGCATTTGACCACATTTA)This paperN/ApC.SIREN.puro sh*PINX1* (CCTTCAGCAAGAGAGTTTAAT)This paperN/ApC.SIREN.puro sh*ZNF267*-1 (TACTCGTTCCTCCAATCTTAT)This paperN/ApC.SIREN.puro sh*ZNF267*-2 (ATCAATATAGGAAGGTCTTTA)This paperN/ApC.SIREN.puro sh*MBD1* (CACCAACCTTCCAAGTGTAAA)This paperN/ApC.SIREN.puro sh*KIF20A* (CCGATGACGATGTCGTAGTTT)This paperN/ApC.SIREN.puro sh*CWC25* (GATCACAGAAGAAGATGGCA)This paperN/ApC.SIREN.puro sh*ZNF574* (ACCACCTTGTAAGTTCTAAAT)This paperN/ApC.SIREN.puro sh*SMN1*-1 (ATCTGTGAAGTAGCTAATAA)This paperN/ApC.SIREN.puro sh*SMN1*-2 (GGCTATCATACTGGCTATTAT)This paperN/ApC.SIREN.puro sh*CDCA2*-1 (AGACTGGGTTCAGGTTATTTC)This paperN/ApC.SIREN.puro shCDCA2-2 (CCGTTCTCAGTTCTCCTAATA)This paperN/ApHRSIN NL4-3 Vpr IRES SBP-ΔLNGFRThis paperN/ApHRSIN HIV-2 Rod Vpx IRES SBP-ΔLNGFRThis paperN/A**Software and Algorithms**Prism v7.04GraphpadPrism v7.04PANTHER (release 10/10/2018)[@bib59]<http://www.pantherdb.org>Flowjo v10.5.2FlowJo, LLCFlowjo v10.5.2Proteome Discoverer v2.2Thermo Fisher ScientificCat\# OPTON-30808Mascot v2.3Matrix Science<http://www.matrixscience.com/server.html>R Studio v1.0.44R Studio<https://www.rstudio.com>Jalview[@bib90]<http://www.jalview.org>Biocoductor Packages (for LIMMA)[@bib33]<http://www.bioconductor.org>**Other**Vivacon 30kDa MWCO ultrafiltration unitsSartoriusVN01H22

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Edward J.D. Greenwood (<ejdg2@cam.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Cell lines {#sec4.3.1}

CEM-T4 (female) T cells (AIDS Reagent Program, Division of AIDS, NIAD, NIH: Dr. JP Jacobs, ([@bib19]) and J-LAT A1 (male) T cells (AIDS Reagent Program, Division of AIDS, NIAD, NIH: Dr E Verdin, ([@bib38], [@bib37]) were cultured in RPMI supplemented with 10% FCS, 100 units/ml penicillin and 0.1 mg/ml streptomycin at 37°C in 5% CO2. HEK293T (female) embryonic kidney cells (Lehner laboratory stocks) were cultured in DMEM supplemented with 10% FCS, 100 units/ml penicillin and 0.1 mg/ml streptomycin at 37°C in 5% CO2. All cells were confirmed to be mycoplasma negative (MycoAlert, Lonza).

Method Details {#sec4.4}
--------------

### NL4-3 molecular clones {#sec4.4.1}

pNL4-3-dE-EGFP (derived from the HIV-1 molecular clone pNL4-3 but encoding Enhanced Green Fluorescent Protein (EGFP) in the *env* open reading frame (ORF), rendering Env non-functional) was obtained through the AIDS Reagent Program, Division of AIDS, NIAD, NIH: Drs Haili Zhang, Yan Zhou, and Robert Siliciano ([@bib94]) and the complete sequence verified by Sanger sequencing. The ΔVpr mutant was generated by cloning three stop codons into the Vpr open reading frame, immediately after the overlap with Vif to prevent interference with that gene:

#### WT Vpr ORF sequence {#sec4.4.1.1}

ATGGAACAAGCCCCAGAAGACCAAGGGCCACAGAGGGAGCCATACAATGAATGGACACTAGAGCTTTTAGAGGAA.

#### ΔVpr ORF sequence {#sec4.4.1.2}

ATGGAACAAGCCCCAGAAGACCAAGGGCCACAGAGGGAGCCATACAATGAATGGACACTAGAGCTT[TAATAGTAA]{.ul}

### Viral stocks {#sec4.4.2}

VSVg-pseudotyped NL4-3-dE-EGFP HIV viral stocks were generated by co-transfection with pMD.G (VSVg) as previously described ([@bib23]). NL4-3-dE-EGFP HIV viral stocks were titerd by infection/transduction of known numbers of relevant target cells under standard experimental conditions followed by flow cytometry for GFP and CD4, using Anti-CD4-AF647 (clone OKT4; BioLegend) at 48 hr to identify % infected cells. Single Vpr and Vpx proteins were expressed in a modified dual promotor pHRSIN ([@bib87]) vector in which Vpr or Vpx expression is driven by the rous sarcoma virus (RSV) promotor, and Emerald GFP expression is driven by the ubiquitin promotor. Virus was generated by co-transfection with pCMVdr8.91 and pMD.G ([@bib97]) in 293T as previously described ([@bib23]). Infectious MOI was normalized by infection in the absence of reverse transcription (RTi) inhibitors, which were included where specified (see below). GenBank accession numbers of the untagged sequences for the Vpr and Vpx proteins used are given in the [Key Resources Table](#sec4.1){ref-type="sec"}. Amino acid sequences were codon optimized, modified to include a HA tag, and synthesized as double stranded DNA (IDT), inserted into the empty vector construct by Gibson assembly, and confirmed by sanger sequencing.

### Lentivector for shRNA expression {#sec4.4.3}

For lentiviral DCAF1 shRNA-mediated knockdown, hairpins were cloned into pHRSIREN-PGK-hygro, with transduced cells selected for hygromycin resistance. The same methodology was used to clone other target shRNA haripins, into pHRSIREN-PGK-puro (encoding puromycin resistance). Gene specific target sequences were chosen from the Broad institute GPP web portal, and are provided in the forward orientation in the [Key Resources Table](#sec4.1){ref-type="sec"}.

### CEM-T4 T cell infections {#sec4.4.4}

CEM-T4 T cells were infected with concentrated NL4-3-dE-EGFP or pHRSIN lentiviral stocks by spinoculation at 800 × g for 1 h in a non-refrigerated benchtop centrifuge in complete media supplemented with 10 mM HEPES. Where reverse transcription treatment was specified (RTi), cells were incubated with zidovudine (10 μM) and efavirenz (100 nM) (AIDS Reagent Program, Division of AIDS, NIAD, NIH) for 1 hr prior to spinoculation, and inhibitors maintained at these concentrations during subsequent cell culture. For MS experiments, cells were subject to dead cell removal (magnetic dead cell removal kit, Miltenyi). Subsequent sample preparation, TMT labeling, and MS are described below, at the end of this section.

### Immunoblotting {#sec4.4.5}

Antibodies against the following proteins were used for immunoblot, listed by manufacturer: Atlas antibodies: TASOR (HPA006735). Bethyl: BBX (A303-151A), HLTF (A300-230A), RALY (A302-070A), ZNF512B (A303-234A). Cell Signaling Technology: SMN1/2 (2F1). Novus: ESCO2 (NB100-87021). Origene: UNG2 (2C12). Proteintech: Vpr (51143-I-AP). Santa Cruz: CCNB1 (SC-245), ZGPAT (SC-515524). Sigma: β-actin (AC74). Abcam: p24 (ab9071), VCP (ab11433). The following secondary antibodies were used: goat anti-mouse-HRP and goat anti-rabbit-HRP (immunoblot, Jackson ImmunoResearch, West Grove, PA). Blots were immersed in chemiluminescent substrate (SuperSignal West Pico or Dura, Thermo Fisher Scientific), and signal was visualized using X-ray film or the iBright CL1000 imaging system (Thermo Fisher Scientific).

### ShRNA knockdown confirmation by RT-PCR {#sec4.4.6}

Total RNA was extracted using the RNeasy Plus Mini kit (QIAGEN). Total RNA (250 ng) was reverse transcribed into cDNA using a poly(d)T primers and SuperScript III Reverse Transcriptase (Invitrogen) following the manufacturer's instructions. Real-time qRT--PCR was performed using the ABI 7500 Real-Time PCR system (Applied Biosystems) and SYBR Green PCR Master Mix (Applied Biosystems), with cycling parameters of 50°C for 2 min and 95°C for 5 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. The gene-of-interest specific primer pairs were predesigned and purchased from Sigma-Aldrich as KiCqStart primers. The sequences are detailed in the key resources table. The difference in the amount of input cDNA was normalized to an internal control of GAPDH ([@bib7]).

### 7-AAD staining {#sec4.4.7}

Cells were fixed in ice cold 70% ethanol for at least 30 minutes, washed with PBS and stained in 25ug/ml 7-AAD for 15 minutes before acquisition on a BD FACSCalibur. Analysis was carried out in Flowjo, v.10.5.2. Dead cells and doublets were excluded by gating on forward scatter, side scatter, and fluorescent area and height. Univariate cell cycle modeling was carried out using the Watson pragmatic method in Flowjo.

### Immunoprecipitation Mass spectrometry (IP-MS) {#sec4.4.8}

Prior to infection with Vpr positive or negative lentivirus, CEM-T4 T cells were treated for two hours with the pan-cullin inhibitor MLN4924, 500nm (Millipore). 24 hours post infection, cells were lysed in 1% NP-40 (IGEPAL CA-630, Sigma-Aldrich), with benzonase (Sigma-Aldrich) at 2000 units/ml. Lysates were pre-cleared with IgG-Sepharose (GE Healthcare, UK) and incubated for 3 hr at 4°C with anti-HA coupled to agarose beads (EZview Red Anti-HA Affinity Gel, Sigma-Aldrich). After washing in 0.5% NP-40, samples were eluted with 0.5 mg/ml HA peptide (Sigma-Aldrich) at 37°C for 1 hr. Proteins defined as co-immunoprecipitating with Vpr were detected with at least 3 peptides in the Vpr condition, not identified in the control condition, and were present in \< 20% of IP-MS available in the Crapome v1.1 database ([@bib58]).

### Labeling with amino acids in cell culture (Pulsed-SILAC) {#sec4.4.9}

For SILAC labeling, CEM-T4 T cells were grown for at least 7 cell divisions in SILAC RPMI lacking lysine and arginine (Thermo Fisher Scientific) supplemented with 10% dialysed FCS (GIBCO, Thermo Fisher Scientific), 100 units/ml penicillin and 0.1 mg/ml streptomycin, 280 mg/L proline (Sigma, UK) and medium (K4, R6; Cambridge Isotope Laboratories, Tewksbury, MA) or heavy (K8, R10; Cambridge Isotope Laboratories) ^13^C/^15^N-containing lysine (K) and arginine (R) at 50 mg/L. At 0 h, cells were washed in media containing only light (^12^C /^14^N) lysine and arginine and were maintained in this media for the duration of the experiment.

### J-LAT reactivation experiments {#sec4.4.10}

JLAT A1 cells were transduced with Cre recombinase, NL4-3 Vpr or HIV-2 ROD Vpx within a pHRSIN IRES SBP-ΔLNGFR vector ([@bib54]). 24 h after transduction, cells were treated with 2 ng/ml TNFα (PeproTech, 300-01A). After an additional 24 h cells were stained with anti-CD271 (NGFR)-APC (clone ME20.4, Biolegend), and analyzed for NGFR and GFP expression by flow cytometry. Cells were gated for NGFR+ cells to exclude non-transduced cells. Flow cytometry data was acquired on a BD FACSCalibur.

### Sample Preparation for Mass spectrometry {#sec4.4.11}

Samples were prepared using three different methods depending on the experiment. Initial infection experiment ([Figure 1](#fig1){ref-type="fig"}) was by SDC-FASP. Vpr particle ([Figure 2](#fig2){ref-type="fig"}) and shRNA ([Figure S1](#mmc1){ref-type="supplementary-material"}) experiments were by PreOmics NHS-iST sample preparation Kit. pSILAC and IP-MS experiments were by SP3.

#### SDC-FASP {#sec4.4.11.1}

Samples prepared essentially according to the protocol in [@bib46]. Briefly samples were lysed in 50mM TEAB (pH8.5) 2% SDS, reduced and alkylated with TCEP/Iodoacetamide, quantified by BCA assay. 50ug of each sample was diluted with TEAB/8M urea for loading onto 30kDa ultrafiltration devices. Samples were washed 3 times with 500uL urea buffer and 3 times with digestion buffer (TEAB/0.5% sodium deoxycholate) before resuspending in 50uL digestion buffer containing 1ug trypsin and incubating overnight at 37 degrees. After digestion samples were spun through the filters and filters washed with 50uL TEAB. SDC was removed by acidification and two phase partitioning with ethyl acetate before vacuum drying and labeling with TMT reagents according to the manufacturer's instructions.

#### PreOmics iST {#sec4.4.11.2}

Samples lysed in kit lysis buffer and quantified by BCA assay. 25ug of each sample was digested essentially according to manufacturer's instructions, scaling volumes for a digestion of 25ug total protein.

#### SP3 {#sec4.4.11.3}

Samples were lysed in 50mM TEAB (pH8.5) 2% SDS (IP-MS were adjusted to 2% SDS), reduced and alkylated with TCEP/Iodoacetamide before digestion using the SP3 method ([@bib34]). Briefly, carboxylate modified paramagnetic beads are added to the sample and protein is bound to the beads by acidification with formic acid and addition of acetonitrile (ACN, final 50%). The beads are then washed sequentially with 100% ACN, 70% Ethanol (twice) and 100% ACN. 10-20uL TEAB (Triethylammonium bicarbonate) pH8 and 0.1% Sodium deoxycholate (SDC) is then added to the washed beads along with trypsin. Samples were then incubated overnight at 37 degrees with periodic shaking at 2000rpm. After digestion, peptides are immobilised on beads by addition of 200-400uL ACN and washed twice with 100uL ACN before eluting in 19uL 2% DMSO and removing the eluted peptide from the beads.

### Offline high pH reversed-phase (HpRP) peptide fractionation {#sec4.4.12}

For whole cell proteome samples HpRP fractionation was conducted on an Ultimate 3000 UHPLC system (Thermo Scientific) equipped with a 2.1 mm × 15 cm, 1.7μ Aqcuity BEH C18 column (Waters, UK). Solvent A was 3% ACN, Solvent B was 100% ACN, solvent C was 200 mM ammonium formate (pH 10). Throughout the analysis solvent C was kept at a constant 10%. The flow rate was 400 μL/min and UV was monitored at 280 nm. Samples were loaded in 90% A for 10 min before a gradient elution of 0%--10% B over 10 min (curve 3), 10%--34% B over 21 min (curve 5), 34%--50% B over 5 mins (curve 5) followed by a 10 min wash with 90% B. 15 s (100 μL) fractions were collected throughout the run. Peptide containing fractions were orthogonally recombined into 24 fractions (i.e., fractions 1, 25, 49, 73, 97 combined) and dried in a vacuum centrifuge. Fractions were stored at −80°C prior to analysis.

### Mass spectrometry {#sec4.4.13}

Data were acquired on an Orbitrap Fusion mass spectrometer (Thermo Scientific) coupled to an Ultimate 3000 RSLC nano UHPLC (Thermo Scientific). HpRP fractions were resuspended in 20 μl 5% DMSO 0.5% TFA and 10uL injected. Fractions were loaded at 10 μl/min for 5 min on to an Acclaim PepMap C18 cartridge trap column (300 um × 5 mm, 5 um particle size) in 0.1% TFA. After loading a linear gradient of 3%--32% solvent B was used for sample separation over a column of the same stationary phase (75 μm × 50 cm, 2 μm particle size) before washing at 90% B and re-equilibration. Solvents were A: 0.1% FA and B:ACN/0.1% FA. 3h gradients were used for whole cell proteomics samples, 1h gradients for IP-MSs.

An SPS/MS3 acquisition was used for TMT experiments and was run as follows. MS1: Quadrupole isolation, 120'000 resolution, 5e5 AGC target, 50 ms maximum injection time, ions injected for all parallelisable time. MS2: Quadrupole isolation at an isolation width of m/z 0.7, CID fragmentation (NCE 35) with the ion trap scanning out in rapid mode from m/z 120, 8e3 AGC target, 70 ms maximum injection time, ions accumulated for all parallelisable time. In synchronous precursor selection mode the top 10 MS2 ions were selected for HCD fragmentation (65NCE) and scanned out in the orbitrap at 50'000 resolution with an AGC target of 2e4 and a maximum accumulation time of 120 ms, ions were not accumulated for all parallelisable time. The entire MS/MS/MS cycle had a target time of 3 s. Dynamic exclusion was set to ± 10 ppm for 90 s, MS2 fragmentation was trigged on precursor ions 5e3 counts and above. For IP-MS, MS2 instead used HCD fragmentation (NCE 34) and a maximum injection time of 250ms and had a target cycle time of 2 s. For pSILAC MS1 was acquired at 240'000 resolution.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Description of statistical tests and n values are provided in the figure legends. Anova and Fisher's exact test analysis were carried out as described in figure legends using Graphpad Prism (v7.04).

### Gene ontology enrichment {#sec4.5.1}

Gene ontology enrichment analysis was carried out using the statistical overrepresentation test of PANTHER (release 10/10/2018) ([@bib59]), using the web interface at: <http://www.pantherdb.org/>, and using the GO Ontology database (release 06/09/2018), ([@bib1], [@bib84]). Lists of proteins highly significantly depleted or increased by Vpr were compared to a background list of proteins quantitated in the two experiments used to define those lists. p values shown are the results of a Fisher's exact test with Bonferroni correction. In the case of GO: Cellular compartment analysis, this is highly conservative as it is corrected for all 1061 possible cellular compartment terms, not just those curated. When calculating the proportion of proteins with a specific GO term, only proteins with a GO term of that class were included in the denominator.

### MS Data processing and analysis {#sec4.5.2}

For TMT labeled samples data were searched by Mascot within Proteome Discoverer 2.1 in two rounds of searching. First search was against the UniProt Human reference proteome (26/09/17) ([@bib86]), the HIV proteome and compendium of common contaminants (GPM). The second search took all unmatched spectra from the first search and searched against the human trEMBL database (Uniprot, 26/09/17). The following search parameters were used. MS1 Tol: 10 ppm, MS2 Tol: 0.6 Da. Enzyme: Trypsin (/P). MS3 spectra were used for reporter ion based quantitation with a most confident centroid tolerance of 20 ppm. PSM FDR was calculated using Mascot percolator and was controlled at 0.01% for 'high' confidence PSMs and 0.05% for 'medium' confidence PSMs. Normalization was automated and based on total s/n in each channel. Protein/peptide abundance was calculated and output in terms of 'scaled' values, where the total s/n across all reporter channels is calculated and a normalized contribution of each channel is output. Proteins/peptides satisfying at least a 'medium' FDR confidence were taken forth to statistical analysis in R (v3.3.1) ([@bib67]). This consisted of a moderated t test (Limma) with Benjamini-Hochberg correction for multiple hypotheses to provide a q value for each comparison ([@bib33], [@bib76]). IP-MS were submitted to a similar search workflow with quantitative data being derived from MS1 spectra via proteome discover minora feature detector node. For pSILAC experiments data were processed in MaxQuant and searched using Andromeda with similar search parameters ([@bib10]). MaxQuant output was uploaded into Perseus for calculation of significance B ([@bib85]). Where conditions were not carried out in triplicate, downstream analysis was limited to proteins identified with at least 3 unique peptides.

### Phylogenetic tree of Vpr sequences {#sec4.5.3}

An existing nucleic acid sequence alignment of representative Vpr sequences from HIV-1, HIV-2 and SIVs from 22 primate species was downloaded from the Los Alamos National Laboratories HIV database (<https://hiv.lanl.gov/content/sequence/NEWALIGN/align.html>). A tree was generated using the percentage identity average distance in jalview ([@bib90]) and visualized in Figtree (<http://tree.bio.ed.ac.uk/software/figtree>). Sequences from 5 primate species not falling into the highlighted linages are not shown. *Cercopithecus* lineage includes closely related viruses from primates of the *Miopithecus* and *Piliocolobus* genera.

Data and Software Analysis {#sec4.6}
--------------------------

In addition to [Table S1](#mmc2){ref-type="supplementary-material"}, which includes data from all of the proteomics experiments carried out here, proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE ([@bib89]) partner repository. The accession number for the data reported in this paper is PRIDE: [PXD013221](pride:PXD013221){#intref0145}.
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